secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001140361-24-027994
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant subsidiary Dermavant renegotiates debt, reduces potential payments by over $300M
--------------------------------------------------------------------------------

- Dermavant caps RIPSA royalties at $6M/yr for FY2025-2027, reducing near-term cash outflow.
- Credit Agreement maturity extended to May 2028; interest rate increased to 12.25% from 10%.
- NovaQuest fixed quarterly payments of $176.3M eliminated; up to $141M in commercial milestones also eliminated.
- Roivant commits $195M in convertible preferred equity at 1.5x liquidation preference; DSL issues ~13.2% common shares to lenders.
- Post-closing, Roivant owns ~87% of DSL common/preferred (~82% fully diluted).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124027994/0001140361-24-027994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124027994/ef20030253_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-027994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer